Jon Ellis
Director/Board Member bij Orchard Therapeutics (Europe) Ltd.
Profiel
Momenteel bekleedt Jon Ellis de functie van Vice President & Head-Science & Technology bij GlaxoSmithKline Plc. Hij zit ook in de raad van bestuur van Orchard Therapeutics (Europe) Ltd. en Orchard Therapeutics Plc. Dr. Ellis behaalde een doctoraat aan de Universiteit van Cambridge, een MBA aan het Henley Management College en een bachelor- en masterdiploma aan het Magdalene College.
Actieve functies van Jon Ellis
| Bedrijven | Functie | Begin |
|---|---|---|
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Director/Board Member | 02-08-2018 |
Eerdere bekende functies van Jon Ellis
| Bedrijven | Functie | Einde |
|---|---|---|
| GSK PLC | Chief Tech/Sci/R&D Officer | 01-08-2022 |
| ORCHARD THERAPEUTICS PLC | Director/Board Member | 16-06-2021 |
Opleiding van Jon Ellis
| University of Cambridge | Doctorate Degree |
| Henley Management College | Masters Business Admin |
| Magdalene College | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| GSK PLC | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
